Search 

Brace Pharmaceuticals is based in Rockville, MD, and is a strategic investment company formed by Brazil-based pharma company EMS S/A. Brace investment structure varies depending on a company’s development stage; for early-stage opportunities Brace typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities Brace is more likely to form strategic partnerships that involve rights to an asset. Brace is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

Brace Pharmaceuticals invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities. Drug-device combinations will also be considered, but Brace does not invest in diagnostics. The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.

CDRD Ventures Inc. (CVI) is the commercialization vehicle of the Centre for Drug Research and Development (CDRD), Canada's national drug development and commercialization center that was founded in 2007 and is based in Vancouver, Canada. CVI seeks to advance promising drug development projects from CDRD using internal funds and through partnerships with international pharmaceutical companies, venture capital firms, biotech companies, and other funding agencies. CVI also seeks to in-license technologies from industry or non-CDRD affiliated research institutions. The firm considers both small molecule and biologic innovative technologies in virtually any therapeutic area.

CitareTx founded in 2008 is a venture development and investment firm based in Houston Texas. The firm provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $5K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic but prefers companies to be based in Texas. The firm is actively seeking new opportunities.

Clayton Biotechnologies commercializes technologies that are developed and owned by the Clayton Foundation for Research and its supporting entities through research programs at leading research hospitals and institutions in the US and Switzerland.

We have several projects in various stages of development from discovery to advanced pre-clinical that are available for licensing, collaboration, and the creation of new start-up ventures.

Clayton Biotechnologies has a significant portfolio of technologies to offer for licensing and collaboration. 

Some of our featured technologies:

- Urocortins and analogues for Diabetes

- Fc engineering of aglycosylated antibodies

- Granzyme B - a potent payload for antibody drug conjugates (ADC)

- Alk4-Fc, a Cripto antagonist for Cancer

- TEAD gene and peptide therapies for ocular neovascular disease

- Stem cell therapy program for Parkinson's Disease

- Vaccines and Diagnostics for Ehrlichioses

- Biomarker for personalized breast cancer therapy

- YESS - engineering of proteases

- OCT Image Guided Smart Laser Knife Diagnosis and Therapy in Small Spaces

To date, 9 products based on Clayton Foundation discoveries have been have been successfully commercialized through the creation of start-up companies and out-licensing

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.